- Home
- CLLS vs EIC Comparison
CLLS vs EIC Comparison
Compare CLLS & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | EIC |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 228.8M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CLLS | EIC |
|---|---|---|
| Price | $1.41 | $9.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.33 | ★ $12.63 |
| AVG Volume (30 Days) | ★ 167.8K | 92.1K |
| Earning Date | 05-08-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 13.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $9.17 |
| 52 Week High | $5.48 | $13.55 |
Technical Indicators
Market Signals| Indicator | CLLS | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 22.93 | 22.14 |
| Support Level | $1.25 | $9.33 |
| Resistance Level | $3.47 | $10.14 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 8.33 | 0.00 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.